This company has been marked as potentially delisted and may not be actively trading. LogicBio Therapeutics (LOGC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrendsBuy This Stock LOGC vs. MYTE, KRUS, FIGS, PLAY, BLMN, HLF, CARS, ETD, SPTN, and CURVShould you be buying LogicBio Therapeutics stock or one of its competitors? The main competitors of LogicBio Therapeutics include MYT Netherlands Parent B.V. (MYTE), Kura Sushi USA (KRUS), FIGS (FIGS), Dave & Buster's Entertainment (PLAY), Bloomin' Brands (BLMN), Herbalife (HLF), Cars.com (CARS), Ethan Allen Interiors (ETD), SpartanNash (SPTN), and Torrid (CURV). These companies are all part of the "retail/wholesale" sector. LogicBio Therapeutics vs. MYT Netherlands Parent B.V. Kura Sushi USA FIGS Dave & Buster's Entertainment Bloomin' Brands Herbalife Cars.com Ethan Allen Interiors SpartanNash Torrid LogicBio Therapeutics (NASDAQ:LOGC) and MYT Netherlands Parent B.V. (NYSE:MYTE) are both small-cap retail/wholesale companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Does the MarketBeat Community favor LOGC or MYTE? LogicBio Therapeutics received 66 more outperform votes than MYT Netherlands Parent B.V. when rated by MarketBeat users. Likewise, 64.08% of users gave LogicBio Therapeutics an outperform vote while only 45.45% of users gave MYT Netherlands Parent B.V. an outperform vote. CompanyUnderperformOutperformLogicBio TherapeuticsOutperform Votes9164.08% Underperform Votes5135.92% MYT Netherlands Parent B.V.Outperform Votes2545.45% Underperform Votes3054.55% Does the media prefer LOGC or MYTE? In the previous week, MYT Netherlands Parent B.V. had 2 more articles in the media than LogicBio Therapeutics. MarketBeat recorded 2 mentions for MYT Netherlands Parent B.V. and 0 mentions for LogicBio Therapeutics. MYT Netherlands Parent B.V.'s average media sentiment score of 1.71 beat LogicBio Therapeutics' score of 0.00 indicating that MYT Netherlands Parent B.V. is being referred to more favorably in the news media. Company Overall Sentiment LogicBio Therapeutics Neutral MYT Netherlands Parent B.V. Very Positive Do insiders and institutionals believe in LOGC or MYTE? 46.1% of LogicBio Therapeutics shares are held by institutional investors. Comparatively, 10.1% of MYT Netherlands Parent B.V. shares are held by institutional investors. 8.1% of LogicBio Therapeutics shares are held by company insiders. Comparatively, 1.9% of MYT Netherlands Parent B.V. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, LOGC or MYTE? LogicBio Therapeutics has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500. Comparatively, MYT Netherlands Parent B.V. has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Do analysts rate LOGC or MYTE? MYT Netherlands Parent B.V. has a consensus price target of $14.00, suggesting a potential upside of 46.60%. Given MYT Netherlands Parent B.V.'s stronger consensus rating and higher possible upside, analysts plainly believe MYT Netherlands Parent B.V. is more favorable than LogicBio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LogicBio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MYT Netherlands Parent B.V. 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is LOGC or MYTE more profitable? MYT Netherlands Parent B.V. has a net margin of -3.98% compared to LogicBio Therapeutics' net margin of -141.03%. MYT Netherlands Parent B.V.'s return on equity of -5.88% beat LogicBio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LogicBio Therapeutics-141.03% -81.98% -52.13% MYT Netherlands Parent B.V. -3.98%-5.88%-3.63% Which has better valuation & earnings, LOGC or MYTE? MYT Netherlands Parent B.V. has higher revenue and earnings than LogicBio Therapeutics. MYT Netherlands Parent B.V. is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLogicBio Therapeutics$287M0.74-$317M-$5.79-1.39MYT Netherlands Parent B.V.$881.44M0.93-$26.95M-$0.43-22.21 SummaryMYT Netherlands Parent B.V. beats LogicBio Therapeutics on 12 of the 18 factors compared between the two stocks. Get LogicBio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LOGC vs. The Competition Export to ExcelMetricLogicBio TherapeuticsCatalog & mail IndustryRetail SectorNASDAQ ExchangeMarket Cap$211.55M$157.53M$24.92B$8.42BDividend YieldN/AN/A169.81%4.10%P/E Ratio-1.39N/A24.1719.69Price / Sales0.740.293.97118.34Price / CashN/A3.2319.4134.62Price / Book0.901.066.074.50Net Income-$317M-$98.89M$784.05M$248.32M LogicBio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LOGCLogicBio Therapeutics0.8278 of 5 stars$8.05+0.6%N/A+51.5%$211.55M$287M-1.3962MYTEMYT Netherlands Parent B.V.2.0785 of 5 stars$9.54-2.0%$14.00+46.8%+86.5%$817.57M$881.44M-22.191,240Positive NewsKRUSKura Sushi USA2.4762 of 5 stars$66.33-1.9%$77.20+16.4%-36.1%$801.60M$258.44M-97.542,100Positive NewsFIGSFIGS1.4719 of 5 stars$4.56-2.6%$4.50-1.3%-21.0%$760.59M$561.17M76.00310Negative NewsPLAYDave & Buster's Entertainment3.7908 of 5 stars$21.31-1.4%$33.00+54.9%-60.4%$735.81M$2.13B10.5523,258Analyst RevisionBLMNBloomin' Brands3.8355 of 5 stars$8.40-4.7%$13.75+63.7%-66.2%$713.42M$3.93B-76.3687,000Positive NewsHLFHerbalife4.5066 of 5 stars$6.93-1.8%$11.50+65.9%-39.6%$705.80M$4.95B2.7810,100Positive NewsAnalyst DowngradeCARSCars.com3.5042 of 5 stars$10.85-0.9%$18.30+68.7%-45.2%$689.28M$718M18.711,700Positive NewsETDEthan Allen Interiors3.6963 of 5 stars$27.05-1.9%$32.00+18.3%-10.4%$687.88M$622.92M11.374,240Positive NewsInsider TradeSPTNSpartanNash3.2103 of 5 stars$19.74-0.5%$15.00-24.0%-5.9%$668.12M$9.55B-1,974.0016,500News CoveragePositive NewsUpcoming EarningsDividend AnnouncementCURVTorrid1.1326 of 5 stars$5.83+0.3%$4.75-18.5%-9.5%$608.23M$1.10B38.872,060News CoveragePositive News Related Companies and Tools Related Companies MYT Netherlands Parent B.V. Alternatives Kura Sushi USA Alternatives FIGS Alternatives Dave & Buster's Entertainment Alternatives Bloomin' Brands Alternatives Herbalife Alternatives Cars.com Alternatives Ethan Allen Interiors Alternatives SpartanNash Alternatives Torrid Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LOGC) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
